Company
Iterum Therapeutics plc
Headquarters: Dublin, Ireland
Employees: 7
CEO: Mr. Corey N. Fishman
Market Cap
$41.8 Million
USD as of Jan. 1, 2025
Iterum Therapeutics plc Categories
Ireland Healthcare BiotechnologyIreland Healthcare Ireland Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Iterum Therapeutics plc has the following listings and related stock indices.
Stock: NASDAQ: ITRM wb_incandescent